Form 8-K FIVE PRIME THERAPEUTICS For: Aug 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics (FPRX) Misses Q2 EPS by 1c
August 6, 2015 5:07 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.45), $0.01 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.92 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
... More